Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

[Pharmacodynamic parameters to evaluate antibiotic cover as empirical treatment].

Aguilar L, Granizo JJ.

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):165-6. doi: 10.1016/j.eimc.2010.12.009. Spanish. No abstract available.

PMID:
21334784
2.

Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain.

Isla A, Trocóniz IF, Canut A, Labora A, Martín-Herrero JE, Pedraz JL, Gascón AR.

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):167-73. doi: 10.1016/j.eimc.2010.05.008.

PMID:
21334779
4.
5.

Pharmacodynamic target attainment of oral beta-lactams for the empiric treatment of acute otitis media in children.

Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP.

Paediatr Drugs. 2008;10(5):329-35.

PMID:
18754699
7.

Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media.

Ghaffar F, Muniz LS, Katz K, Reynolds J, Smith JL, Davis P, Friedland IR, McCracken GH Jr.

Clin Infect Dis. 2000 Oct;31(4):875-80.

PMID:
11049764
8.

Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.

Pichichero ME, Doern GV, Kuti JL, Nicolau DP.

Paediatr Drugs. 2008;10(6):391-7. doi: 10.2165/0148581-200810060-00006.

PMID:
18998749
9.

Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media.

Block SL.

Pediatr Infect Dis J. 1997 Apr;16(4):449-56. Review.

PMID:
9109158
10.

The problem of resistant bacteria for the management of acute otitis media.

Barnett ED, Klein JO.

Pediatr Clin North Am. 1995 Jun;42(3):509-17. Review.

PMID:
7761138
11.

Oral beta-lactams in the treatment of acute otitis media.

Block SL, Doern GV, Pfaller MA.

Diagn Microbiol Infect Dis. 2007 Mar;57(3 Suppl):19S-30S. Review.

PMID:
17349460
12.

Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.

Blondeau JM, Vaughan D, Laskowski R, Borsos S; Canadian Antimicrobial Study Group..

Int J Antimicrob Agents. 2001 Jun;17(6):457-64.

PMID:
11397615
13.
14.

Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.

Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Sahm DF.

J Antimicrob Chemother. 1999 Dec;44(6):749-59.

PMID:
10590275
15.

Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles.

Dagan R.

Int J Infect Dis. 2003 Mar;7 Suppl 1:S21-6. Review.

PMID:
12839704
16.

Antibiotic treatment failures in acute otitis media.

Stotka JL.

Pediatr Ann. 1992 May;21(5):272-5. No abstract available.

PMID:
1625940
17.

[Bacteriological aspects in the mid term report of the CDTR clinical trial for PRSP and BLNAR infections].

Ubukata K.

Jpn J Antibiot. 2001 May;54 Suppl B:91-5. Japanese. No abstract available.

PMID:
12638153
18.

Treatment of acute otitis media - challenges in the era of antibiotic resistance.

Dagan R.

Vaccine. 2000 Dec 8;19 Suppl 1:S9-S16. Review.

PMID:
11163457
20.

Evaluation of antimicrobial treatments in children with acute otitis media in Spain: a pharmacokinetic-pharmacodynamic (PK/PD) approach.

Beobide I, Canut A, Gascón AR, Isla A, García-Rey C, De La Maza I, Labora A, Pedraz JL.

J Chemother. 2005 Dec;17(6):628-35.

PMID:
16433193
Items per page

Supplemental Content

Support Center